The below Parliamentary question was asked by Margaret Hodge on 2016-10-11.
To ask the Secretary of State for International Development, pursuant to the Answer of 2 September 2016 to Question 44352, for what contracts the largest three total payments were made to (a) PwC, (b) Deloitte, (c) Ernst and Young and (d) KPMG in the last three years.
Rory Stewart
Detail on all DFID spend is available via our departmental website.
The below Parliamentary question was asked by Margaret Hodge on 2015-11-13.
To ask the Secretary of State for Foreign and Commonwealth Affairs, if he will ensure that any agreement on a central registry of beneficial ownership in Montserrat includes access for the public with legitimate reason.
James Duddridge
I refer the Right Honourable Lady to the answer given by my Hon Friend the member for Hertfordshire South West (David Gauke), the Financial Secretary to the Treasury on 16 October to questions 10437, 10438 and 10448, which sets out the criteria we expect the Overseas Territories to meet in relation to their central register of company beneficial ownership, or similarly effective system. We are in discussions with the Montserrat authorities on this and are offering technical assistance as they develop their proposals.
The below Parliamentary question was asked by Margaret Hodge on 2016-04-21.
To ask the Minister for the Cabinet Office, whether an equality impact assessment has been undertaken in respect of the policy of including an anti-lobbying clause in government grant agreements.
Matthew Hancock
Departments are currently working with grant recipients on the implementation of the guidance, in relation to the new grants clause. This will include a consideration of equality impact issues, which will be reported centrally to the Cabinet Office for assessment, with regards to finalising the central policy by 1 May 2016.
The below Parliamentary question was asked by Margaret Hodge on 2016-09-02.
To ask the Secretary of State for Work and Pensions, if he will publish a list of all secondees to his Department from (a) PwC, (b) Deloitte, (c) Ernst and Young, (d) KPMG and (e) other consulting firms in the last three financial years; and what the role was of each of those secondees.
Caroline Nokes
The information requested is not collated centrally and could only be provided at disproportionate cost.
The below Parliamentary question was asked by Margaret Hodge on 2016-09-02.
To ask the Secretary of State for Foreign and Commonwealth Affairs, how many times his Department has used the services of (a) PwC, (b) Deloitte, (c) Ernst and Young, (d) KPMG and (e) other consulting firms in the last three financial years; and what (i) work was undertaken and (ii) the cost to the public purse was on each such occasion.
Sir Alan Duncan
DELOITTE
2013/14:£69,000
2014/15:£33,000
2015/16:£121,000
ERNST & YOUNG
2013/14:£480,000
2014/15:£328,000
2015/16:£181,000
KPMG
2013/14:£140,000
2014/15:£116,000
2015/16:£132,000
PWC
2013/14:£355,000
2014/15:£377,000
2015/16:£1,420,000
Consultants
2013/14:£1,500,000
2014/15:£1,600,000
2015/16:£1,100,000
All applicable expenditure with these companies is published as part of HMG’s Transparency Agenda at https://www.gov.uk/government/collections/foreign-office-spend-over-25000.
The below Parliamentary question was asked by Margaret Hodge on 2016-10-19.
To ask the Attorney General, on what date the Serious Fraud Office first received information on allegations of bribery and corruption at Rolls Royce.
Robert Buckland
The Serious Fraud Office first received information concerning allegations of bribery and corruption at Rolls Royce in November 2011.
The below Parliamentary question was asked by Margaret Hodge on 2015-11-13.
To ask the Secretary of State for Foreign and Commonwealth Affairs, what assessment he has made of the progress made by Montserrat in meeting the Prime Minister’s ambition for a public register of beneficial ownership since June 2013.
James Duddridge
I refer the Right Honourable Lady to the answer given by my Hon Friend the member for Hertfordshire South West (David Gauke), the Financial Secretary to the Treasury to questions 10437, 10438 and 10448, which sets out the criteria we expect the Overseas Territories to meet in relation to their central register of company beneficial ownership, or similarly effective system. We are in discussions with the Montserrat authorities on this and are offering technical assistance as they develop their proposals.
The below Parliamentary question was asked by Margaret Hodge on 2016-04-27.
To ask the Secretary of State for Health, how he plans to ensure that an additional 20,000 patients a year will have their cancers genetically tested as part of the Government’s Cancer Taskforce strategy; and what data he plans to collect on those people who are tested.
Jane Ellison
The independent Cancer Taskforce recognised the need for more accessible molecular diagnostic provision in its report, Achieving World-Class Cancer Outcomes: A Strategy for England 2015-2020, published in July 2015.
Following this, in September 2015, we confirmed a commitment from NHS England to implement the recommendations on molecular diagnostics. This will mean that around 25,000 additional people a year will have their cancers genetically tested to identify the most effective treatments. NHS England is currently working with partners across the healthcare system to produce an implementation plan to determine how best to take forward the Taskforce’s recommendations.
Regional Genetic Laboratories are central to all NHS Genomic Medicine Centres and have been the focal point for adoption of genomic technologies into healthcare for over 40 years. These laboratories are currently the focus of an NHS England Specialised Commissioning intended re-procurement exercise, the invitation to tender for which is due to be launched towards the end of the year. The re-procurement aims to create a new genomic laboratory infrastructure for the National Health Service in England based on centralised and local genomic laboratory hubs to support rare, inherited and acquired disease, as well as the future personalised medicine requirements inclusive of molecular diagnostics in stratified medicine.
In September 2015, the NHS England Board approved the development of a Personalised Medicine Strategy for the NHS, to be discussed at the NHS England Board in the summer.
This work will build on the 100,000 Genomes Project, in which the NHS is a key delivery partner. The Project will sequence whole genomes from eligible patients with rare diseases and cancers. It is moving the NHS to a new model of diagnosis and treatment based on understanding of underlying genetic causes and drivers of disease and a comprehensive phenotypic characterisation of the disease (rather than deduction from symptoms and individual diagnostic tests). This will be critical in guiding the approach to molecular diagnostics.
In addition, changes to the section 118 guidance implemented in the national tariff payment system for molecular diagnostics from April will support clinical change and practice. This includes a number of molecular diagnostic tests to be funded separately by commissioners for the first three years before being incorporated into national prices for treatment episodes.
The below Parliamentary question was asked by Margaret Hodge on 2016-09-02.
To ask the Secretary of State for Work and Pensions, how many times his Department has used the services of (a) PwC, (b) Deloitte, (c) Ernst and Young, (d) KPMG and (e) other consulting firms in the last three financial years; and what (i) work was undertaken and (ii) the cost to the public purse was on each such occasion.
Caroline Nokes
We are unable to provide the requested information on the number of times the Department for Work and Pensions has used the services of consulting firms, including details of the work undertaken and cost to the public purse for each occasion. To do so would incur a disproportional cost to the Department because of how the data is held on our systems, and the time and resource required for extracting and analysing it.
The below Parliamentary question was asked by Margaret Hodge on 2016-09-02.
To ask the Secretary of State for Health, if he will publish a list of all secondees to his Department from (a) PwC, (b) Deloitte, (c) Ernst and Young, (d) KPMG and (e) other consulting firms in the last three financial years; and what the role was of each of those secondees.
David Mowat
In line with privacy and data protection legislation as well as standing Cabinet Office instructions, the exact numbers and details of individual roles cannot be published. This is to prevent the personal identification of individuals either directly or in combination with other published information.
There have been two appointments in total into Senior Civil Servant roles as follows, during the years in question as follows:
|
Name |
Start date |
Grade |
End date |
Seconding Organisation |
Role |
|
Robin Furnell |
24/08/2015 |
SCS1 |
31/12/2016 |
Accenture |
Contract Management Function Implementation Lead |
|
Nicole Mather |
22/04/2014 |
SCS2 |
22/10/2016 |
Deloitte (formally seconded to BEIS and part-time to DH) |
Director – Office for Life Sciences |
During the same period of time, at lower grades the following table summarises the disclosable information
|
Company |
Numbers |
Grades of role |
|
PwC |
5 or fewer |
HEO and SEO |
|
Deloitte |
5 or fewer |
Analyst and G7 |
|
Ernst and Young |
5 or fewer |
G7 |
|
KPMG |
0 |
– |
|
Accenture |
0 |
– |
The above information does not include secondees to the Department’s agencies or arms’ length bodies.